Vicore Pharma to Present at the Jefferies Global Healthcare Conference

Location: New York, New York 
Format: Fireside chat and 1×1 meetings 
Webcast: Link  
Presentation Date and Time: Thursday June 4th at 2:35 PM 
Participants: Ahmed Mousa, CEO, and Bernt van den Blink, CMO 
 
For more information, please contact: 
Megan Richards, VP of IR and Comms, +1 978 269-4372, megan.richards@vicorepharma.com 
Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com 
 
About Vicore Pharma 
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. 
Vicore Pharma is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. www.vicorepharma.com